Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_assertion type Assertion NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_head.
- NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_assertion description "[Current pharmacologic treatment of IBD, including 5-aminosalycylate, steroids, and immunomodulator therapy, are mainly aimed at suppressing inflammation non-specifically, except biologic therapies such as anti-tumor necrosis factor molecule, which block specific proinflammatory molecules.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_provenance.
- NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_assertion evidence source_evidence_literature NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_provenance.
- NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_assertion SIO_000772 19647622 NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_provenance.
- NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_assertion wasDerivedFrom befree-2016 NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_provenance.
- NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_assertion wasGeneratedBy ECO_0000203 NP754839.RATFR6_-y8SJJOOVPL26F8fCpGJB-QmkjKIKNEiYFsHpo130_provenance.